CCL

Összesen 17 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM073208
035-os BibID:(WoS)000398387200006 (Scopus)85019025865
Első szerző:Aggarwal, Rohit
Cím:2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis / Rohit Aggarwal, Lisa G. Rider, Nicolino Ruperto, Nastaran Bayat, Brian Erman, Brian M. Feldman, Chester V. Oddis, Anthony A. Amato, Hector Chinoy, Robert G. Cooper, Maryam Dastmalchi, David Fiorentino, David Isenberg, James D. Katz, Andrew Mammen, Marianne de Visser, Steven R. Ytterberg, Ingrid E. Lundberg, Lorinda Chung, Katalin Danko, Ignacio García-De la Torre, Yeong Wook Song, Luca Villa, Mariangela Rinaldi, Howard Rockette, Peter A. Lachenbruch, Frederick W. Miller, Jiri Vencovsky, International Myositis Assessment and Clinical Studies Group, Paediatric Rheumatology International Trials Organisation
Dátum:2017
ISSN:0003-4967
Megjegyzések:To develop response criteria for adult dermatomyositis (DM) and polymyositis (PM). Expert surveys, logistic regression, and conjoint analysis were used to develop 287 definitions using core set measures. Myositis experts rated greater improvement among multiple pairwise scenarios in conjoint analysis surveys, where different levels of improvement in 2 core set measures were presented. The PAPRIKA (Potentially All Pairwise Rankings of All Possible Alternatives) method determined the relative weights of core set measures and conjoint analysis definitions. The performance characteristics of the definitions were evaluated on patient profiles using expert consensus (gold standard) and were validated using data from a clinical trial. The nominal group technique was used to reach consensus. Consensus was reached for a conjoint analysis-based continuous model using absolute per cent change in core set measures (physician, patient, and extramuscular global activity, muscle strength, Health Assessment Questionnaire, and muscle enzyme levels). A total improvement score (range 0-100), determined by summing scores for each core set measure, was based on improvement in and relative weight of each core set measure. Thresholds for minimal, moderate, and major improvement were ?20, ?40, and ?60 points in the total improvement score. The same criteria were chosen for juvenile DM, with different improvement thresholds. Sensitivity and specificity in DM/PM patient cohorts were 85% and 92%, 90% and 96%, and 92% and 98% for minimal, moderate, and major improvement, respectively. Definitions were validated in the clinical trial analysis for differentiating the physician rating of improvement (p<0.001). The response criteria for adult DM/PM consisted of the conjoint analysis model based on absolute per cent change in 6 core set measures, with thresholds for minimal, moderate, and major improvement.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Dermatomyositis
Polymyositis
Treatment
Megjelenés:Annals Of The Rheumatic Diseases. - 76 : 5 (2017), p. 792-801. -
További szerzők:Rider, Lisa G. Ruperto, Nicolino Bayat, Nastaran Erman, Brian Feldman, Brian M. Oddis, Chester V. Amato, Anthony A. Chinoy, Hector Cooper, Robert G. Dastmalchi, Maryam Fiorentino, David Isenberg, David A. Katz, James D. Mammen, Andrew Visser, Marianne de Ytterberg, Steven R. Lundberg, Ingrid Chung, Lorinda Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Torre, Ignacio García-De la Song, Yeong Wook Villa, Luca Rinaldi, Mariangela Rockette, Howard Lachenbruch, Peter A. Miller, Frederick W. Vencovsky, Jiri International Myositis Assessment and Clinical Studies Group Paediatric Rheumatology International Trials Organisation (PRINTO)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM073210
Első szerző:Aggarwal, Rohit
Cím:2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheu / Rohit Aggarwal, Lisa G. Rider, Nicolino Ruperto, Nastaran Bayat, Brian Erman, Brian M. Feldman, Chester V. Oddis, Anthony A. Amato, Hector Chinoy, Robert G. Cooper, Maryam Dastmalchi, David Fiorentino, David Isenberg, James D. Katz, Andrew Mammen, Marianne de Visser, Steven R. Ytterberg, Ingrid E. Lundberg, Lorinda Chung, Katalin Danko, Ignacio García-De la Torre, Yeong Wook Song, Luca Villa, Mariangela Rinaldi, Howard Rockette, Peter A. Lachenbruch, Frederick W. Miller, Jiri Vencovsky, International Myositis Assessment and Clinical Studies Group, Paediatric Rheumatology International Trials Organisation
Dátum:2017
ISSN:2326-5191
Megjegyzések:OBJECTIVE:To develop response criteria for adult dermatomyositis (DM) and polymyositis (PM).METHODS:Expert surveys, logistic regression, and conjoint analysis were used to develop 287 definitions using core set measures. Myositis experts rated greater improvement among multiple pairwise scenarios in conjoint analysis surveys, where different levels of improvement in 2 core set measures were presented. The PAPRIKA (Potentially All Pairwise Rankings of All Possible Alternatives) method determined the relative weights of core set measures and conjoint analysis definitions. The performance characteristics of the definitions were evaluated on patient profiles using expert consensus (gold standard) and were validated using data from a clinical trial. The nominal group technique was used to reach consensus.RESULTS:Consensus was reached for a conjoint analysis-based continuous model using absolute percent change in core set measures (physician, patient, and extramuscular global activity, muscle strength, Health Assessment Questionnaire, and muscle enzyme levels). A total improvement score (range 0-100), determined by summing scores for each core set measure, was based on improvement in and relative weight of each core set measure. Thresholds for minimal, moderate, and major improvement were ?20, ?40, and ?60 points in the total improvement score. The same criteria were chosen for juvenile DM, with different improvement thresholds. Sensitivity and specificity in DM/PM patient cohorts were 85% and 92%, 90% and 96%, and 92% and 98% for minimal, moderate, and major improvement, respectively. Definitions were validated in the clinical trial analysis for differentiating the physician rating of improvement (P?<?0.001).CONCLUSION:The response criteria for adult DM/PM consisted of the conjoint analysis model based on absolute percent change in 6 core set measures, with thresholds for minimal, moderate, and major improvement.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Arthritis & Rheumatology 69 : 5 (2017), p. 898-910. -
További szerzők:Rider, Lisa G. Ruperto, Nicolino Bayat, Nastaran Erman, Brian Feldman, Brian M. Oddis, Chester V. Amato, Anthony A. Chinoy, Hector Cooper, Robert G. Dastmalchi, Maryam Fiorentino, David Isenberg, David A. Katz, James D. Mammen, Andrew Visser, Marianne de Ytterberg, Steven R. Lundberg, Ingrid Chung, Lorinda Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Torre, Ignacio García-De la Song, Yeong Wook Villa, Luca Rinaldi, Mariangela Rockette, Howard Lachenbruch, Peter A. Miller, Frederick W. Vencovsky, Jiri International Myositis Assessment and Clinical Studies Group Paediatric Rheumatology International Trials Organisation (PRINTO)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM083545
035-os BibID:(WOS)000537433000017 (Scopus)85084167516
Első szerző:Betteridge, Zoe
Cím:Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis / Zoe Betteridge, Hector Chinoy, Jiri Vencovsky, John Winer, Kiran Putchakayala, Pauline Ho, Ingrid Lundberg, Katalin Danko, Robert Cooper, Neil McHugh
Dátum:2020
ISSN:1462-0324 1462-0332
Megjegyzések:OBJECTIVES: To describe the prevalence and clinical associations of autoantibodies to a novel autoantigen, eukaryotic initiation factor 3 (eIF3), detected in idiopathic inflammatory myositis. METHODS: Sera or plasma from 678 PM patients were analysed for autoantigen specificity by radio-labelled protein immunoprecipitation (IPP). Samples immunoprecipitating the same novel autoantigens were further analysed by indirect immunofluorescence and IPP using pre-depleted cell extracts. The autoantigen was identified through a combination of IPP and MALDI-TOF mass spectrometry, and confirmed using commercial antibodies and IPP-western blots. Additional samples from patients with DM (668), DM-overlap (80), PM-overlap (191), systemic sclerosis (150), systemic lupus erythematosus (200), Sjogren's syndrome (40), rheumatoid arthritis (50) and healthy controls (150) were serotyped by IPP as disease or healthy controls. RESULTS: IPP revealed a novel pattern in three PM patients (0.44%) that was not found in disease-specific or healthy control sera. Indirect immunofluorescence demonstrated a fine cytoplasmic speckled pattern for all positive patients. Mass spectrometry analysis of the protein complex identified the target autoantigen as eIF3, a cytoplasmic complex with a role in the initiation of translation. Findings were confirmed by IPP-Western blotting. The three anti-eIF3-positive patients had no history of malignancy or interstitial lung disease, and had a favourable response to treatment. CONCLUSION: We report a novel autoantibody in 0.44% of PM patients directed against a cytoplasmic complex of proteins identified as eIF3. Although our findings need further confirmation, anti-eIF3 appears to correlate with a good prognosis and a favourable response to treatment.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
autoantibodies
autoantigens
myositis
Megjelenés:Rheumatology. - 59 : 5 (2020), p. 1026-1030. -
További szerzők:Chinoy, Hector Vencovsky, Jiri Winer, John Putchakayala, Kiran Ho, Pauline Lundberg, Ingrid Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Cooper, Robert G. McHugh, Neil
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM078908
Első szerző:Betteridge, Zoe
Cím:Clinical Phenotypes of Caucasian Adult and Juvenile Dermatomyositis Patients with Anti-MDA5 Autoantibodies / Zoe Betteridge, Sarah Tansley, Harsha Gunawardena, Lucy R. Wedderburn, Hector Chinoy, Robert G. Cooper, Jiri Vencovsky, Lenka Plestilova, Ingrid E. Lundberg, Katalin Danko, Melinda Vincze, Neil McHugh, UK JDRG, EuMyoNet
Dátum:2019
Megjegyzések:Background/Purpose: Autoantibodies to MDA5 have been previously reported in Japanese patients with dermatomyositis (DM) and are associated with clinically-amyopathic DM and rapidly progressing interstitial lung disease (ILD). These autoantibodies also occur in juvenile Japanese DM patients in association with ILD. Anti-MDA5 has also been reported in a cohort of mixed ethnicity, where it was found to be associated with ILD and severe vasculopathy. Here we report on the frequency and clinical manifestations of anti-MDA5 autoantibodies in a large international multicenter cohort of Caucasian adult and juvenile myositis patients. Methods: Serum was available from 1331 adult myositis patients (480 DM) recruited to the EuMyoNet repository and 172 JDM patients recruited to the UK JDRG. Sera were screened for autoantibodies by immunoprecipitation (IPP) using radio-labelled K562 cell extract. Sera with immunoprecipitates at approximately 140 kDa were tested for anti-MDA5 autoantibodies by ELISA using recombinant MDA5 (Cambridge BioSciences). Clinical data were collected on standardised proformas. Sera from 169 systemic sclerosis, 40 SLE and 50 healthy controls were also analyzed by IPP. Statistical analysis was performed using SPSS and Fishers Exact Test. Results: Anti-MDA5 autoantibodies were found in the sera of 12 JDM patients and 25 adults. The frequency in the JDM cohort was 7.0%, in comparison to 1.9% in the overall adult myositis population and 3.8% in the adult DM group. Anti-MDA5 autoantibodies were not found in any patients with PM or any control sera. As with previous reports, there was an association between ILD and anti-MDA5 (p_0.044) in the adultDMpatients. However, contrary to previous reports, this was not seen to be rapidly progressing, with no known ILD related fatalities in the anti-MDA5 positive group. In comparison, ILD was not found to be a significant association in the JDM anti-MDA5 positive group, with no patients having ILD reported as a clinical manifestation. Similarly to previous report, anti-MDA5 positive patients had significantly more ulceration (skin: p_0.047 and mouth: p_0.039), in the JDM cohort, compared with the anti-MDA5 negative group. Whilst ulceration data was unavailable in the adult population, the presence of anti-MDA5 was significantly associated with Gottron's papules (p_0.001). Conclusion: We report the presence of anti-MDA5 autoantibodies in a large cohort of Caucasian JDM and adult myositis patients. The frequency of anti-MDA5 autoantibodies varies between adults and children, along with differences in the clinical profile. As with previous reports, the presence of anti-MDA5 is associated with the presence of severe cutaneous features in both JDM and adults. However, in this study ILD was only an association in the adult population, suggesting differences in pathogenesis or aetiology. This study also highlights differences in clinical manifestations between different ethnic groups, with the ILD in our adult patients being
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
Megjelenés:Arthritis & Rheumatism. - 64 : 10 (2019), p. S715. -
További szerzők:Tansley, Sarah Gunawardena, Harsha Wedderburn, Lucy R. Chinoy, Hector Cooper, Robert G. Vencovsky, Jiri Plestilova, Lenka Lundberg, Ingrid Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Nagy-Vincze Melinda (1985-) (orvos) McHugh, Neil UK JDRG EuMyoNet
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM078900
035-os BibID:(PMID)30992170
Első szerző:Betteridge, Zoe
Cím:Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients / Z. Betteridge, S. Tansley, G. Shaddick, H. Chinoy, R. G. Cooper, R. P. New, J. B. Lilleker, J. Vencovsky, L. Chazarain, K. Danko, M. Nagy-Vincze, L. Bodoki, M. Dastmalchi, L. Ekholm, I. E. Lundberg, N. McHugh, UKMyonet contributors
Dátum:2019
ISSN:0896-8411
Megjegyzések:OBJECTIVES: To determine prevalence and co-existence of myositis specific autoantibodies (MSAs) and myositis associated autoantibodies (MAAs) and associated clinical characteristics in a large cohort of idiopathic inflammatory myopathy (IIM) patients. METHODS: Adult patients with confirmed IIM recruited to the EuroMyositis registry (n?=?1637) from four centres were investigated for the presence of MSAs/MAAs by radiolabelled-immunoprecipitation, with confirmation of anti-MDA5 and anti-NXP2 by ELISA. Clinical associations for each autoantibody were calculated for 1483 patients with a single or no known autoantibody by global linear regression modelling. RESULTS: MSAs/MAAs were found in 61.5% of patients, with 84.7% of autoantibody positive patients having a sole specificity, and only three cases (0.2%) having more than one MSA. The most frequently detected autoantibody was anti-Jo-1 (18.7%), with a further 21 specificities each found in 0.2-7.9% of patients. Autoantibodies to Mi-2, SAE, TIF1, NXP2, MDA5, PMScl and the non-Jo-1 tRNA-synthetases were strongly associated (p?<?0.001) with cutaneous involvement. Anti-TIF1 and anti-Mi-2 positive patients had an increased risk of malignancy (OR 4.67 and 2.50 respectively), and anti-SRP patients had a greater likelihood of cardiac involvement (OR 4.15). Interstitial lung disease was strongly associated with the anti-tRNA synthetases, anti-MDA5, and anti-U1RNP/Sm. Overlap disease was strongly associated with anti-PMScl, anti-Ku, anti-U1RNP/Sm and anti-Ro60. Absence of MSA/MAA was negatively associated with extra-muscular manifestations. CONCLUSIONS: Myositis autoantibodies are present in the majority of patients with IIM and identify distinct clinical subsets. Furthermore, MSAs are nearly always mutually exclusive endorsing their credentials as valuable disease biomarkers.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Autoantibodies
Autoimmune
Dermatomyositis
Myositis
Polymyositis
Megjelenés:Journal Of Autoimmunity. - 101 (2019), p. 48-55. -
További szerzők:Tansley, Sarah Shaddick, G. Chinoy, Hector Cooper, Robert G. New, Robert Paul Lilleker, James B. Vencovsky, Jiri Chazarain, L. Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Nagy-Vincze Melinda (1985-) (orvos) Bodoki Levente (1986-) (PhD hallgató) Dastmalchi, Maryam Ekholm, L. Lundberg, Ingrid McHugh, Neil UKMyonet contributors
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM073206
Első szerző:Bottai, Matteo
Cím:EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups : a methodology report / Matteo Bottai, Anna Tjärnlund, Giola Santoni, Victoria P. Werth, Clarissa Pilkington, Marianne de Visser, Lars Alfredsson, Anthony A. Amato, Richard J. Barohn, Matthew H. Liang, Jasvinder A. Singh, Rohit Aggarwal, Snjolaug Arnardottir, Hector Chinoy, Robert G. Cooper, Katalin Danko, Mazen M. Dimachkie, Brian M. Feldman, Ignacio García-De La Torre, Patrick Gordon, Taichi Hayashi, James D. Katz, Hitoshi Kohsaka, Peter A. Lachenbruch, Bianca A. Lang, Yuhui Li, Chester V. Oddis, Marzena Olesinka, Ann M. Reed, Lidia Rutkowska-Sak, Helga Sanner, Albert Selva-O'Callaghan, Yeong Wook Song, Jiri Vencovsky, Steven R. Ytterberg, Frederick W. Miller, Lisa G. Rider, Ingrid E. Lundberg, International Myositis Classification Criteria Project consortium, Euromyositis register and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository
Dátum:2017
ISSN:2056-5933
Megjegyzések:OBJECTIVE:To describe the methodology used to develop new classification criteria for adult and juvenile idiopathic inflammatory myopathies (IIMs) and their major subgroups.METHODS:An international, multidisciplinary group of myositis experts produced a set of 93 potentially relevant variables to be tested for inclusion in the criteria. Rheumatology, dermatology, neurology and paediatric clinics worldwide collected data on 976 IIM cases (74% adults, 26% children) and 624 non-IIM comparator cases with mimicking conditions (82% adults, 18% children). The participating clinicians classified each case as IIM or non-IIM. Generally, the classification of any given patient was based on few variables, leaving remaining variables unmeasured. We investigated the strength of the association between all variables and between these and the disease status as determined by the physician. We considered three approaches: (1) a probability-score approach, (2) a sum-of-items approach criteria and (3) a classification-tree approach.RESULTS:The approaches yielded several candidate models that were scrutinised with respect to statistical performance and clinical relevance. The probability-score approach showed superior statistical performance and clinical practicability and was therefore preferred over the others. We developed a classification tree for subclassification of patients with IIM. A calculator for electronic devices, such as computers and smartphones, facilitates the use of the European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria.CONCLUSIONS:The new EULAR/ACR classification criteria provide a patient's probability of having IIM for use in clinical and research settings. The probability is based on a score obtained by summing the weights associated with a set of criteria items
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
autoimmune diseases
dermatomyositis
polymyositis
Megjelenés:RMD Open. - 3 : 2 (2017), p. 1-10. -
További szerzők:Tjärnlund, Anna Santoni, Giola Werth, Victoria P. Pilkington, Clarissa Visser, Marianne de Alfredsson, Lars Amato, Anthony A. Barohn, Richard J. Liang, Matthew H. Singh, Jasvinder A. Aggarwal, Rohit Arnardottir, Snjolaug Chinoy, Hector Cooper, Robert G. Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Dimachkie, Mazen M. Feldman, Brian M. Torre, Ignacio García-De la Gordon, Patrick Hayashi, Taichi Katz, James D. Kohsaka, Hitoshi Lachenbruch, Peter A. Lang, Bianca A. Li, Yuhui Oddis, Chester V. Olesinka, Marzena Reed, Ann M. Rutkowska-Sak, Lidia Sanner, Helga Selva-O'Callaghan, Albert Song, Yeong Wook Vencovsky, Jiri Ytterberg, Steven R. Miller, Frederick W. Rider, Lisa G. Lundberg, Ingrid International Myositis Classification Criteria Project consortium Euromyositis register and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM040271
Első szerző:Chinoy, Hector
Cím:Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies : a European-wide case study / Chinoy H., Adimulam S., Marriage F., New P., Vincze M., Zilahi E., Kapitány A., Gyetvai A., Ekholm L., Novota P., Remakova M., Charles P., McHugh N. J., Padyukov L., Alfredsson L., Vencovsky J., Lundberg I. E., Danko K., Ollier W. E., Cooper R. G.
Dátum:2012
Megjegyzések:Objectives: HLA-DRB1*03 is strongly associated withanti-Jo-1-positive idiopathic infl ammatory myopathies (IIM)and there is now increasing evidence that Jo-1 antigen ispreferentially expressed in lung tissue. This study examinedwhether smoking was associated with the development ofanti-Jo-1 antibodies in HLA-DRB1*03-positive IIM.Methods IIM cases were selected with concurrentinformation regarding HLA-DRB1 status, smoking historyand anti-Jo-1 antibody status. DNA was genotypedat DRB1 using a commercial sequence-specifi coligonucleotide kit. Anti-Jo-1 antibody status wasestablished using a line blot assay or immunoprecipitation.Results 557 Caucasian IIM patients were recruited fromHungary (181), UK (99), Sweden (94) and Czech Republic(183). Smoking frequency was increased in anti-Jo-1-positive IIM cases, and reached statistical signifi cance inHungarian IIM (45% Jo-1-positive vs 17% Jo-1-negative,OR 3.94, 95% CI 1.53 to 9.89, p<0.0001). A strongassociation between HLA-DRB1*03 and anti-Jo-1status was observed across all four cohorts (DRB1*03frequency: 74% Jo-1-positive vs 35% Jo-1-negative, OR5.55, 95% CI 3.42 to 9.14, p<0.0001). The frequency ofHLA-DRB1*03 was increased in smokers. The frequencyof anti-Jo-1 was increased in DRB1*03-positive smokersvs DRB1*03-negative non-smokers (42% vs 8%, OR 7.75,95% CI 4.21 to 14.28, p<0.0001) and DRB1*03-positivenon-smokers (42% vs 31%, p=0.08). In DRB1*03-negative patients, anti-Jo-1 status between smokers andnon-smokers was not signifi cantly different. No signifi cantinteraction was noted between smoking and DRB1*03status using anti-Jo-1 as the outcome measure.Conclusion Smoking appears to be associated withan increased risk of possession of anti-Jo-1 in HLADRB1*03-positive IIM cases. The authors hypothesisethat an interaction between HLA-DRB1*03 and smokingmay prime the development of anti-Jo-1 antibodies.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
myopathy
Megjelenés:Annals of the Rheumatic Diseases 71 : 6 (2012), p. 961-965. -
További szerzők:Adimulam, S. Marriage, F. New, Paul Nagy-Vincze Melinda (1985-) (orvos) Zilahi Erika (1964-) (molekuláris biológus) Kapitány Anikó (1979-) (molekuláris biológus) Gyetvai Ágnes Ekholm, L. Novota, P. Remakova, M. Charles, Peter McHugh, Neil Padyukov, Leonid Alfredsson, Lars Vencovsky, Jiri Lundberg, Ingrid Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Ollier, William E. Cooper, Robert G.
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM073045
Első szerző:Ibrahim, Fowzia
Cím:Second-line agents in myositis : 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids / Fowzia Ibrahim, Ernest Choy, Patrick Gordon, Caroline J. Doré, Alan Hakim, George Kitas, David Isenberg, Bridget Griffiths, Bryan Lecky, Kuntal Chakravarty, John Winer, Katalin Danko, Robert G. Cooper, Beverley White-Alao, David L. Scott
Dátum:2015
ISSN:1462-0324
Megjegyzések:OBJECTIVE:Ciclosporin and MTX are used in idiopathic inflammatory myopathies (DM and PM) when patients incompletely respond to glucocorticoids. Their effectiveness is unproved in randomized controlled trials (RCTs). We evaluated their benefits in a placebo-controlled factorial RCT.METHODS:A 56-week multicentre factorial-design double-blind placebo-controlled RCT compared steroids alone, MTX (15-25 mg weekly) plus steroids, ciclosporin (1-5 mg/kg/day) plus steroids and all three treatments. It enrolled adults with myositis (by Bohan and Peter criteria) with active disease receiving corticosteroids.RESULTS:A total of 359 patients were screened and 58 randomized. Of the latter, 37 patients completed 12 months of treatment, 7 were lost to follow-up and 14 discontinued treatment. Patients completing 12 months of treatment showed significant improvement (P < 0.001 on paired t-tests) in manual muscle testing (14% change), walking time (22% change) and function (9% change). Intention to treat and completer analyses indicated that ciclosporin monotherapy, MTX monotherapy and ciclosporin/MTX combination therapy showed no significant treatment effects in comparison with placebo.CONCLUSION:Neither MTX nor ciclosporin (by themselves or in combination) improved clinical features in myositis patients who had incompletely responded to glucocorticoids.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Rheumatology 54 : 6 (2015), p. 1050-1055. -
További szerzők:Choy, Ernest Gordon, Patrick Doré, Caroline J. Hakim, Alan Kitas, George Isenberg, David A. Griffiths, Bridget Lecky, Bryan Chakravarty, Kuntal Winer, John Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Cooper, Robert G. White-Alao, Beverley Scott, David L.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

9.

001-es BibID:BIBFORM077422
035-os BibID:(Cikkazonosító)e51 (WoS)000440169600005 (Scopus)85049024561
Első szerző:Lilleker, James B.
Cím:Response to: "Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria" by Cavagna et al / James B. Lilleker, Jiri Vencovsky, Guochun Wang, Lucy R. Wedderburn, Louise P. Diederichsen, Jens Schmidt, Paula Jordan, Olivier Benveniste, Maria Giovanna Danieli, Katalin Dankó, Nguyen Thi Phuong Thuy, Monica Vázquez-Del Mercado, Helena Andersson, Boel De Paepe, Jan L. De Bleecker, Britta Maurer, Liza J. McCann, Nicolo Pipitone, Neil McHugh, Zoe Betteridge, Paul New, Robert G. Cooper, William E. Ollier, Janine A. Lamb, Niels Steen Krogh, Ingrid E. Lundberg, Hector Chinoy, EuroMyositis contributors
Dátum:2017
ISSN:0003-4967
Tárgyszavak:Orvostudományok Klinikai orvostudományok hozzászólás
Megjelenés:Annals of The Rheumatic Diseases. - 77 : 8 (2017), p. 1. -
További szerzők:Vencovsky, Jiri Wang, Guochun Wedderburn, Lucy R. Diederichsen, Louise Pyndt Schmidt, Jens Jordan, Paula Benveniste, Olivier Danieli, Maria Giovanna Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Nguyen, Thi Le Phuong Vazquez-Del Mercado, Monica Andersson, Helena De Paepe, Boel De Bleecker, Jan Maurer, Britta McCann, Liza J. Pipitone, Nicolo McHugh, Neil Betteridge, Zoe New, Paul Cooper, Robert G. Ollier, William E. Lamb, Janine A. Krogh, Niels Steen Lundberg, Ingrid Chinoy, Hector EuroMyositis contributors
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

10.

001-es BibID:BIBFORM073211
035-os BibID:(WoS)000417778700010 (Scopus)85038218055
Első szerző:Lilleker, James B.
Cím:The EuroMyositis registry : an international collaborative tool to facilitate myositis research / James B. Lilleker, Jiri Vencovsky, Guochun Wang, Lucy R. Wedderburn, Louise Pyndt Diederichsen, Jens Schmidt, Paula Oakley, Olivier Benveniste, Maria Giovanna Danieli, Katalin Danko, Nguyen Thi Phuong Thuy, Monica Vazquez-Del Mercado, Helena Andersson, Boel De Paepe, Jan L. deBleecker, Britta Maurer, Liza J. McCann, Nicolo Pipitone, Neil McHugh, Zoe E. Betteridge, Paul New, Robert G. Cooper, William E. Ollier, Janine A. Lamb, Niels Steen Krogh, Ingrid E. Lundberg, Hector Chinoy, EuroMyositis contributors
Dátum:2018
ISSN:0003-4967
Megjegyzések:AIMS:The EuroMyositis Registry facilitates collaboration across the idiopathic inflammatory myopathy (IIM) research community. This inaugural report examines pooled Registry data.METHODS:Cross-sectional analysis of IIM cases from 11 countries was performed. Associations between clinical subtypes, extramuscular involvement, environmental exposures and medications were investigated.RESULTS:Of 3067 IIM cases, 69% were female. The most common IIM subtype was dermatomyositis (DM) (31%). Smoking was more frequent in connective tissue disease overlap cases (45%, OR 1.44, 95% CI 1.09 to 1.90, p=0.012). Smoking was associated with interstitial lung disease (ILD) (OR 1.32, 95% CI 1.06 to 1.65, p=0.013), dysphagia (OR 1.43, 95% CI 1.16 to 1.77, p=0.001), malignancy ever (OR 1.78, 95% CI 1.36 to 2.33, p<0.001) and cardiac involvement (OR 2.40, 95% CI 1.60 to 3.60, p<0.001).Dysphagia occurred in 39% and cardiac involvement in 9%; either occurrence was associated with higher Health Assessment Questionnaire (HAQ) scores (adjusted OR 1.79, 95% CI 1.43 to 2.23, p<0.001). HAQ scores were also higher in inclusion body myositis cases (adjusted OR 3.85, 95% CI 2.52 to 5.90, p<0.001). Malignancy (ever) occurred in 13%, most commonly in DM (20%, OR 2.06, 95% CI 1.65 to 2.57, p<0.001).ILD occurred in 30%, most frequently in antisynthetase syndrome (71%, OR 10.7, 95% CI 8.6 to 13.4, p<0.001). Rash characteristics differed between adult-onset and juvenile-onset DM cases ('V' sign: 56%?DM vs 16% juvenile-DM, OR 0.16, 95% CI 0.07 to 0.36, p<0.001). Glucocorticoids were used in 98% of cases, methotrexate in 71% and azathioprine in 51%.CONCLUSION:This large multicentre cohort demonstrates the importance of extramuscular involvement in patients with IIM, its association with smoking and its influence on disease severity. Our findings emphasise that IIM is a multisystem inflammatory disease and will help inform prognosis and clinical management of patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Disease registrieS
Myositis
Megjelenés:Annals Of The Rheumatic Diseases. - 77 : 1 (2018), p. 30-39. -
További szerzők:Vencovsky, Jiri Wang, Guochun Wedderburn, Lucy R. Diederichsen, Louise Pyndt Schmidt, Jens Oakley, Paula Benveniste, Olivier Danieli, Maria Giovanna Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Thuy, Nguyen Thi Phuong Vazquez-Del Mercado, Monica Andersson, Helena De Paepe, Boel deBleecker, Jan L. Maurer, Britta McCann, Liza J. Pipitone, Nicolo McHugh, Neil Betteridge, Zoe New, Paul Cooper, Robert G. Ollier, William E. Lamb, Janine A. Krogh, Niels Steen Lundberg, Ingrid Chinoy, Hector EuroMyositis contributors
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

11.

001-es BibID:BIBFORM073201
Első szerző:Lundberg, Ingrid
Cím:2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups / Ingrid E. Lundberg, Anna Tjärnlund, Matteo Bottai, Victoria P. Werth, Clarissa Pilkington, Marianne de Visser, Lars Alfredsson, Anthony A. Amato, Richard J. Barohn, Matthew H. Liang, Jasvinder A. Singh, Rohit Aggarwal, Snjolaug Arnardottir, Hector Chinoy, Robert G. Cooper, Katalin Danko, Mazen M. Dimachkie, Brian M. Feldman, Ignacio Garcia-De La Torre, Patrick Gordon, Taichi Hayashi, James D. Katz, Hitoshi Kohsaka, Peter A. Lachenbruch, Bianca A. Lang, Yuhui Li, Chester V. Oddis, Marzena Olesinska, Ann M. Reed, Lidia Rutkowska-Sak, Helga Sanner, Albert Selva-O'Callaghan, Yeong-Wook Song, Jiri Vencovsky, Steven R. Ytterberg, Frederick W. Miller, Lisa G. Rider, International Myositis Classification Criteria Project Consortium, Euromyositis Register and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository
Dátum:2017
ISSN:2326-5191
Megjegyzések:OBJECTIVE:To develop and validate new classification criteria for adult and juvenile idiopathic inflammatory myopathies (IIM) and their major subgroups.METHODS:Candidate variables were assembled from published criteria and expert opinion using consensus methodology. Data were collected from 47 rheumatology, dermatology, neurology, and pediatric clinics worldwide. Several statistical methods were utilized to derive the classification criteria.RESULTS:Based on data from 976 IIM patients (74% adults; 26% children) and 624 non-IIM patients with mimicking conditions (82% adults; 18% children), new criteria were derived. Each item is assigned a weighted score. The total score corresponds to a probability of having IIM. Subclassification is performed using a classification tree. A probability cutoff of 55%, corresponding to a score of 5.5 (6.7 with muscle biopsy) "probable IIM," had best sensitivity/specificity (87%/82% without biopsies, 93%/88% with biopsies) and is recommended as a minimum to classify a patient as having IIM. A probability of ?90%, corresponding to a score of ?7.5 (?8.7 with muscle biopsy), corresponds to "definite IIM." A probability of <50%, corresponding to a score of <5.3 (<6.5 with muscle biopsy), rules out IIM, leaving a probability of ?50-<55% as "possible IIM."CONCLUSION:The European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for IIM have been endorsed by international rheumatology, dermatology, neurology, and pediatric groups. They employ easily accessible and operationally defined elements, and have been partially validated. They allow classification of "definite," "probable," and "possible" IIM, in addition to the major subgroups of IIM, including juvenile IIM. They generally perform better than existing criteria.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Arthritis & Rheumatology 69 : 12 (2017), p. 2271-2282. -
További szerzők:Tjärnlund, Anna Bottai, Matteo Werth, Victoria P. Pilkington, Clarissa Visser, Marianne de Alfredsson, Lars Amato, Anthony A. Barohn, Richard J. Liang, Matthew H. Singh, Jasvinder A. Aggarwal, Rohit Arnardottir, Snjolaug Chinoy, Hector Cooper, Robert G. Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Dimachkie, Mazen M. Feldman, Brian M. Torre, Ignacio García-De la Gordon, Patrick Hayashi, Taichi Katz, James D. Kohsaka, Hitoshi Lachenbruch, Peter A. Lang, Bianca A. Li, Yuhui Oddis, Chester V. Olesinka, Marzena Reed, Ann M. Rutkowska-Sak, Lidia Sanner, Helga Selva-O'Callaghan, Albert Song, Yeong Wook Vencovsky, Jiri Ytterberg, Steven R. Miller, Frederick W. Rider, Lisa G. International Myositis Classification Criteria Project consortium Euromyositis register and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

12.

001-es BibID:BIBFORM073202
035-os BibID:(WoS)000417061500008 (Scopus)85037677819
Első szerző:Lundberg, Ingrid
Cím:2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups / Ingrid E. Lundberg, Anna Tjärnlund, Matteo Bottai, Victoria P. Werth, Clarissa Pilkington, Marianne de Visser, Lars Alfredsson, Anthony A. Amato, Richard J. Barohn, Matthew H. Liang, Jasvinder A. Singh, Rohit Aggarwal, Snjolaug Arnardottir, Hector Chinoy, Robert G. Cooper, Katalin Dankó, Mazen M. Dimachkie, Brian M. Feldman, Ignacio Garcia-De La Torre, Patrick Gordon, Taichi Hayashi, James D. Katz, Hitoshi Kohsaka, Peter A. Lachenbruch, Bianca A. Lang, Yuhui Li, Chester V. Oddis, Marzena Olesinska, Ann M. Reed, Lidia Rutkowska-Sak, Helga Sanner, Albert Selva-O'Callaghan, Yeong-Wook Song, Jiri Vencovsky, Steven R. Ytterberg, Frederick W. Miller, Lisa G. Rider, International Myositis Classification Criteria Project consortium, Euromyositis register and The Juvenile Dermatomyositis Cohort Biomarker Study and Repository
Dátum:2017
ISSN:0003-4967
Megjegyzések:OBJECTIVE:To develop and validate new classification criteria for adult and juvenile idiopathic inflammatory myopathies (IIM) and their major subgroups.METHODS:Candidate variables were assembled from published criteria and expert opinion using consensus methodology. Data were collected from 47 rheumatology, dermatology, neurology and paediatric clinics worldwide. Several statistical methods were used to derive the classification criteria.RESULTS:Based on data from 976 IIM patients (74% adults; 26% children) and 624 non-IIM patients with mimicking conditions (82% adults; 18% children), new criteria were derived. Each item is assigned a weighted score. The total score corresponds to a probability of having IIM. Subclassification is performed using a classification tree. A probability cut-off of 55%, corresponding to a score of 5.5 (6.7 with muscle biopsy) 'probable IIM', had best sensitivity/specificity (87%/82% without biopsies, 93%/88% with biopsies) and is recommended as a minimum to classify a patient as having IIM. A probability of ?90%, corresponding to a score of ?7.5 (?8.7 with muscle biopsy), corresponds to 'definite IIM'. A probability of <50%, corresponding to a score of <5.3 (<6.5 with muscle biopsy), rules out IIM, leaving a probability of ?50?to <55% as 'possible IIM'.CONCLUSIONS:The European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for IIM have been endorsed by international rheumatology, dermatology, neurology and paediatric groups. They employ easily accessible and operationally defined elements, and have been partially validated. They allow classification of 'definite', 'probable' and 'possible' IIM, in addition to the major subgroups of IIM, including juvenile IIM. They generally perform better than existing criteria.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
autoimmune disease
dermatomyositis
polymyositis
Megjelenés:Annals of The Rheumatic Diseases. - 76 : 12 (2017), p. 1955-1964. -
További szerzők:Tjärnlund, Anna Bottai, Matteo Werth, Victoria P. Pilkington, Clarissa Visser, Marianne de Alfredsson, Lars Amato, Anthony A. Barohn, Richard J. Liang, Matthew H. Singh, Jasvinder A. Aggarwal, Rohit Arnardottir, Snjolaug Chinoy, Hector Cooper, Robert G. Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Dimachkie, Mazen M. Feldman, Brian M. Torre, Ignacio García-De la Gordon, Patrick Hayashi, Taichi Katz, James D. Kohsaka, Hitoshi Lachenbruch, Peter A. Lang, Bianca A. Li, Yuhui Oddis, Chester V. Olesinka, Marzena Reed, Ann M. Rutkowska-Sak, Lidia Sanner, Helga Selva-O'Callaghan, Albert Song, Yeong Wook Vencovsky, Jiri Ytterberg, Steven R. Miller, Frederick W. Rider, Lisa G. International Myositis Classification Criteria Project consortium Euromyositis register and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 2